Crescita Price To Sales Ratio from 2010 to 2026
| CTX Stock | CAD 0.47 0.02 4.08% |
Price To Sales Ratio | First Reported 2010-12-31 | Previous Quarter 0.66 | Current Value 0.62 | Quarterly Volatility 8.75161487 |
Check Crescita Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Crescita Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Interest Expense of 55.6 K or Selling General Administrative of 10.5 M, as well as many indicators such as Price To Sales Ratio of 0.62, Dividend Yield of 0.0 or PTB Ratio of 0.67. Crescita financial statements analysis is a perfect complement when working with Crescita Therapeutics Valuation or Volatility modules.
Crescita | Price To Sales Ratio |
Evaluating Crescita Therapeutics's Price To Sales Ratio across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Crescita Therapeutics's fundamental strength.
Latest Crescita Therapeutics' Price To Sales Ratio Growth Pattern
Below is the plot of the Price To Sales Ratio of Crescita Therapeutics over the last few years. Price to Sales Ratio is figured by comparing Crescita Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Crescita Therapeutics sales, a figure that is much harder to manipulate than other Crescita Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. It is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period. Crescita Therapeutics' Price To Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Crescita Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 0.40 X | 10 Years Trend |
|
Price To Sales Ratio |
| Timeline |
Crescita Price To Sales Ratio Regression Statistics
| Arithmetic Mean | 7.21 | |
| Geometric Mean | 2.39 | |
| Coefficient Of Variation | 121.30 | |
| Mean Deviation | 8.08 | |
| Median | 0.87 | |
| Standard Deviation | 8.75 | |
| Sample Variance | 76.59 | |
| Range | 18.9788 | |
| R-Value | (0.85) | |
| Mean Square Error | 23.17 | |
| R-Squared | 0.72 | |
| Significance | 0.000018 | |
| Slope | (1.47) | |
| Total Sum of Squares | 1,225 |
Crescita Price To Sales Ratio History
About Crescita Therapeutics Financial Statements
Crescita Therapeutics investors utilize fundamental indicators, such as Price To Sales Ratio, to predict how Crescita Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Price To Sales Ratio | 0.66 | 0.62 |
Other Information on Investing in Crescita Stock
Crescita Therapeutics financial ratios help investors to determine whether Crescita Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Crescita with respect to the benefits of owning Crescita Therapeutics security.